ArticleBMC infectious diseases2005
Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species.
Article in BMC infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis.BMJ open · 2020Pooled it
- Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.BMC infectious diseases · 2006Pooled it
- LAMP-Based Detection ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Epidemiological Characteristics and Mortality Predictors of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2025Article
- Article
- Predictive nomogram for early detection of invasive fungal disease deterioration --- a 10-year retrospective cohort study.BMC infectious diseases · 2025Article
- Neutrophil extracellular traps capture the human pathogen, Candida albicans, in blood and delay hyphal transformation.Journal of leukocyte biology · 2025Article
- Risk of oral candidiasis: profile analysis of patients admitted to the dermatology clinic of a tertiary hospital in southeast of Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Clinical and molecular features of candidemia: a three-year retrospective study in Northern Guizhou, China.Frontiers in cellular and infection microbiology · 2025Article
- Previously Uncharacterized Variants, OCF-E-OCF-J, of the Antifungal Occidiofungin Produced byJournal of natural products · 2024Article
- Review
- Prospecting Plant Extracts and Bioactive Molecules with Antimicrobial Activity in Brazilian Biomes: A Review.Antibiotics (Basel, Switzerland) · 2023Review
- Atypical changes in Candida albicans cells treated with the Venetin-1 complex from earthworm coelomic fluid.Scientific reports · 2023Article
- Organ-specific host differential gene expression analysis in systemic candidiasis: A systems biology approach.Microbial pathogenesis · 2022Article
- Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinicalSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Candidemia in hospitalized cirrhotic patients with bloodstream infection: A retrospective analysis and brief summary of published studies.Journal of the Chinese Medical Association : JCMA · 2022Article
- Cellular and Extracellular Vesicle RNA Analysis in the Global Threat FungusMicrobiology spectrum · 2021Article
- Article
- Inhibition of Phospholipase by Orlistat as an Alternate Therapy to Combat Opportunistic Mycosis Caused by C. albicans.Current microbiology · 2021Article
- Predominance of Candida Glabrata among Non-Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal infections, such as candidemia, caused by Candida species have been increasing. Candidemia is not only associated with a high mortality (30% to 40%) but also extends the length of hospital stay and increases the costs of medical care. Sepsis caused by Candida species is clinically indistinguishable from bacterial infections. Although, the clinical presentations of the patients with candidemia caused by Candida albicans and non-albicans Candida species (NAC) are indistinguishable, the susceptibilities to antifungal agents of these species are different. In this study, we attempted to identify the risk factors for candidemia caused by C. albicans and NAC in the hope that this may guide initial empiric therapy.
methodsA retrospective chart review was conducted during 1996 to 1999 at the Veterans General Hospital-Taipei.
resultsThere were 130 fatal cases of candidemia, including 68 patients with C. albicans and 62 with NAC. Candidemia was the most likely cause of death in 55 of the 130 patients (42.3 %). There was no significant difference in the distribution of Candida species between those died of candidemia and those died of underlying conditions. Patients who had one of the following conditions were more likely to have C. albicans, age > or = 65 years, immunosuppression accounted to prior use of steroids, leukocytosis, in the intensive care unit (ICU), and intravascular and urinary catheters. Patients who had undergone cancer chemotherapy often appeared less critically ill and were more likely to have NAC.
conclusionClinical and epidemiological differences in the risk factors between candidemia caused by C. albicans and NAC may provide helpful clues to initiate empiric therapy for patients infected with C. albicans versus NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.